These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34387593)

  • 41. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials.
    Roviello G; Gatta Michelet MR; D'Angelo A; Nobili S; Mini E
    Clin Transl Oncol; 2020 Jul; 22(7):1033-1039. PubMed ID: 31617061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apalutamide and Overall Survival in Prostate Cancer.
    Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Brookman-May SD; Li S; Zhang K; Rooney B; Lopez-Gitlitz A; Small EJ
    Eur Urol; 2021 Jan; 79(1):150-158. PubMed ID: 32907777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
    J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
    Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
    Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
    Myint ZW; Momo HD; Otto DE; Yan D; Wang P; Kolesar JM
    JAMA Netw Open; 2020 Nov; 3(11):e2025826. PubMed ID: 33201234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A
    Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile.
    Mori K; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Grossmann NC; Rajwa P; Ploussard G; Briganti A; Kimura T; Egawa S; Papalia R; Carrion DM; Fiori C; Shariat SF; Esperto F; Pradere B
    Minerva Urol Nephrol; 2022 Jun; 74(3):292-301. PubMed ID: 34308608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
    Rodriguez-Vida A; Rodríguez-Alonso A; Useros-Rodríguez E; Lopez-Campos F; Amor-Carro O; Arribas-Ruiz A; Martinez-Torres J; Roca-Pardiñas J; Quesada-García A; Muñoz-Del-Toro JR; Juárez-Soto Á
    Clin Genitourin Cancer; 2022 Apr; 20(2):197.e1-197.e10. PubMed ID: 34920959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
    Carles J; Medina-Lopez RA; Puente J; Gómez-Ferrer Á; Nebra JC; Sáez Medina MI; Ribal MJ; Antolín AR; Álvarez-Ossorio JL; Suárez Novo JF; Agut CM; Srinivasan S; Ortiz J; Fizazi K
    Future Oncol; 2023 Apr; 19(12):819-828. PubMed ID: 37222151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A; Méndez-Vidal MJ; Vazquez S; Castro E; Climent MA; Gallardo E; Gonzalez-Billalabeitia E; Lorente D; Maroto JP; Arranz JA
    Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM; O'Day K; Sugarman R; Ramaswamy K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.
    Machidori A; Shiota M; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Eto M
    Urol Oncol; 2021 Jun; 39(6):365.e1-365.e7. PubMed ID: 33077351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
    Morgans AK; Shore N; Cope D; McNatty A; Moslehi J; Gomella L; Sartor O
    Urol Oncol; 2021 Jan; 39(1):52-62. PubMed ID: 32958445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
    Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.